The use of stereotactic ablative body radiotherapy (SABR) for oligoprogressive cancers

Puntos clave

• Stereotactic ablative body radiotherapy improves tumor control in oligoprogressive cancers, potentially reducing local recurrence.
• A treatment regimen utilizing SABR demonstrated a 20% increase in tumor response rates compared to conventional therapies.
• Assessment focused on safety and efficacy, with emphasis on using SABR in patients with limited progression of cancer.
• Findings suggest SABR may offer a targeted approach to managing oligoprogressive cancer cases.